Attention Deficit Hyperactivity Disorder not just a kid’s problem

September 22, 2021

Impact of ADHD into adulthood significant

People with ADHD are often thought of as simply being hyperactive, distracted or generally disorganised. However, there is much more than meets the eye to this attention disorder that is usually associated with children but, interestingly, is also common in adults. 


Dr Laura Comrie, a psychiatrist practicing at Netcare Akeso Kenilworth, points out that there are many misconceptions around ADHD – which stands for Attention Deficit Hyperactivity Disorder – and that it in fact describes a very real and legitimate problem with regulating attention. 


“This largely hereditary neuro-developmental disorder has to do with the wiring of the brain during development. The research indicates that ADHD has persisted since childhood in 25% - 50% of adults who have it. While current figures for adults with ADHD are at around 4% in the general population, it is suspected that this number is much higher but that due to a lack of awareness, it often goes undiagnosed.”


Is this you or someone you know?

Dr Comrie notes that there are three different sub-types of ADHD, each of which present differently.


1. Hyperactive/Impulsive:

  • Fidgety, unable to sit still or wait patiently
  • Talking too much, interrupting others
  • Highly active – as though there is a motor constantly running inside


2. Inattentive:

  • Easily distracted and often day-dreaming; seemingly avoiding dislikes
  • Problems with completing or remembering tasks; making mistakes
  • Losing things often and difficulty in being organised


3. Combined:

  • A combination of the above types of symptoms


“ADHD tends to present more commonly in men, with the Hyperactive/Impulsive type being most prevalent in that sex. These individuals will often choose a line of work that involves physical activity rather than sitting at a desk. Inattentive ADHD is more common in women. It is possible that because Inattentive ADHD is less of a visible concern, it is more undiagnosed than Hyperactive/Impulsive or Combined ADHD. 


“The disorder occurs on a spectrum, so it is more severe in some than in others. Many people are quite functional and have systems in place to help them manage their condition. Those with ADHD often have a strong entrepreneurial spirit as they tend to be creative thinkers and can experience incredible levels of focus on subjects about which they are passionate. At the same time, they can really struggle with more mundane tasks in life, such as doing the bookkeeping or remembering to run an errand, for example. 


“This type of behaviour can be frustrating for family members and colleagues but it is quite literally out of the control of the person with ADHD. Because it is a neurological disorder, it often requires medical intervention to help regulate it. It is most certainly not the case that these individuals lack discipline or are lazy, as some people believe. In fact, they have the potential to make valuable contributions to society, provided they receive the medication, psychotherapy and societal support that they need,” she says. 


Why medication?

Dr Comrie explains that ADHD affects the delivery of two neurotransmitters – namely dopamine and noradrenaline, also known as norepinephrine – to the front part of the brain that controls planning, organisation, maintaining focus during routine tasks and similar neural processes. 


“These neurotransmitters are important for ensuring that such processes in the brain take place effectively. In people with ADHD, dopamine and noradrenaline are not being properly delivered to the front part of the brain, affecting the brain’s function. This has been studied with the use of magnetic resonance imaging (MRI), which has clearly shown measurable differences in the brains of those with ADHD and those without it. 


“Medication is important for these individuals to function in a neurotypical or ‘normal’ world, like school, university or certain workplaces. This helps them to gain and maintain confidence, to absorb and retain information and generally to develop and grow,” she says. 


According to Dr Comrie, ADHD medication works by delivering the missing stimulants, dopamine or noradrenaline, to the brain. “The more common type of medication used assists with the delivery of dopamine and works quickly, sometimes within 20 minutes. It also leaves the system quickly – within four to eight hours. Dosage and type will therefore depend on whether you need short-acting or long-acting medicine. Adults usually require long-acting medicine, because their workday is typically longer than a school day. 


“This type of medication is not a huge commitment, as the person is able to try it out and see fairly quickly if it works for them. Many adults choose to take this medication only when they need it, in circumstances which they know will require strong focus – for example they may skip it on weekends. This medication can however make you feel wired and over-stimulated, in which case the other form of medication needs to be explored. 


“The second type of ADHD medication available works on noradrenaline. This requires you to gradually build up towards the full dosage over ten weeks and must be taken daily without skipping a dose, in order to build and maintain efficacy. This is often seen as the second line in treatment as it is a bigger commitment. 


“The medicines are costly but it is important to weigh up the cost versus benefit ratio against how difficult your life can be without the help. Fortunately, generics have become available in recent years so the medication is more affordable now than previously. Again, ADHD occurs on a spectrum and only those with impaired functioning in daily life really need to consider using medication,” she says. 

Dr Laura Comrie

Dr Laura Comrie

Other factors to consider 

Addressing the concern that many people have around they or their children taking medication for ADHD, Dr Comrie points out that if untreated, ADHD can lead to a serious lack of confidence as well as low academic or career performance. 


“Some individuals are afraid of addiction to ADHD medication. However, by not having the clinical support they need, people with ADHD may seek out the stimulants their brains need elsewhere, such as in certain illegal and seriously addictive drugs. If used properly, ADHD medication can in fact help to avoid substance addiction into adulthood. 


“Upon receiving an ADHD diagnosis, it is important to fully discuss both medication and psychotherapy treatment options with a psychiatrist, as contributing factors such as anxiety or depression need to be taken into account in creating the right treatment programme. 


“The medical management of ADHD can only be improved with a healthy lifestyle such as avoiding stimulants like caffeine, eating a balanced diet, exercising regularly, getting enough sleep and practising daily mindfulness in the form of a breathing exercise, for example. This approach, along with understanding and support from family and colleagues, can go a long way to positively impacting the life of someone with ADHD,” concludes Dr Comrie.

Neurologist Dr. Michael Huth emphasises the importance of understanding different migraine types
May 3, 2025
Migraines affect 15% of the global population, causing severe pain and disrupting daily life. Neurologist Dr. Michael Huth emphasises the importance of understanding different migraine types and their triggers.
Dr Michael de Villiers explains why people can become sick every flu season
April 21, 2025
Dr Michael de Villiers explains why people can become sick every flu season and why the influenza vaccine is generally recommended every year.
Dr Mpho Ramabulana stresses the importance of early detection of colorectal cancer.
April 11, 2025
Colorectal cancer, one of the most prevalent yet preventable cancers, can develop in the colon or rectum, often starting as small polyps that can quietly become malignant if left unchecked. Dr Mpho Ramabulana, a colorectal surgeon and gastroenterologist at Netcare Akasia Hospital, underscores the life-saving power of vigilance and the importance of early detection.
Cardiologist Dr Robert Routier and cardiothoracic intensive care unit manager Sr Nondumiso Fakude
April 1, 2025
Cardiologist Dr Robert Routier urges the public to check their personal risk factors regularly to help prevent or manage cardiovascular disease.
Obstetrician and gynaecologist Dr Natalie Odell
March 26, 2025
The physical strain pregnancy puts on an expectant mother’s body should not be underestimated. An obstetrician gynaecologist offers her insights for alleviating discomfort and promoting wellbeing with exercise and stretching throughout pregnancy.
Dr Patience Sigwadi
March 19, 2025
Dr Patience Sigwadi, a leading paediatric nephrologist practising at Netcare Unitas Hospital in Centurion, has issued an urgent call for increased focus on skills development to address the escalating kidney disease crisis among children in South Africa.
Paediatric Nephrologist Prof Rajendra Bhimma
March 11, 2025
Paediatric Nephrologist Professor Bhimma was recently awarded the Fellowship to acknowledge his extensive work in research, community-based outreach and teaching of paediatric nephrology, among others.
Prof Bhekifa Dube
March 7, 2025
Netcare congratulates Professor Bhekifa Dube on his invitation to join the European Society for Vascular Surgery's clinical practice guidelines committee. His selection as the only specialist from the continent highlights the significance of this achievement on the global stage.
Rare Disease Day on 28 February 2025
February 28, 2025
The lives of millions of South Africans with a litany of rare diseases can be vastly improved, and even saved, by addressing challenges in identifying, studying and treating their conditions. With Rare Disease Day on the 28th of February 2025, the Rare Diseases Access Initiative (RDAI) is driving an evolution of the country’s healthcare, through innovative strategies to better care for over 4.2million people living with an estimated 7000 rare diseases. “As our healthcare system faces significant changes in the years ahead, it is vital that we also advocate for people living with rare diseases in South Africa, especially those with limited healthcare access,” said Kelly du Plessis, CEO of Rare Diseases South Africa (RDSA), a member of RDAI. “As part of our ongoing research and awareness efforts, RDAI has conducted an initial analysis of the incidence and prevalence of rare diseases within the country.” This research will assist in improving access to healthcare, policy development, and patient advocacy, while giving critical insight into the challenges faced by patients. “According to research, some rare diseases affect fewer than 1 in a million people, while others, such as Down syndrome, cystic fibrosis, and haemophilia, have a more recognisable prevalence,” says Dr. Helen Malherbe, RDAI lead researcher on rare disease prevalence data. “Many conditions are undetected, underdiagnosed or misdiagnosed, with too many having no information available about them at all.” The RDAI was formed in 2019 to promote a more favourable environment for those impacted by rare diseases in South Africa. Participants include Ampath, the Board of Healthcare Funders (BHF), Discovery Health, Genetic Counsellors South Africa (SASHG), the Government Employees Medical Scheme (GEMS), Health Funders Association (HFA), Medihelp, Medscheme, North-West University (NWU), Rare Diseases South Africa (RDSA), the South African Medical Association (SAMA) and The South African Medical Technology Industry Association (SAMED). The Council for Medical Schemes (CMS) participates as an observer. In the same year, Rare Disease International signed a memorandum of understanding with the World Health Organisation leading to an international rare disease policy framework. In 2021, the United Nations General Assembly moved to adopt a resolution recognising 300 million people living with rare diseases worldwide. “A general lack of awareness and delayed diagnosis remain major hurdles for those affected by rare diseases. Policymakers and healthcare stakeholders need to prioritise access to treatment, diagnosis, and support for rare disease patients,” says Bada Pharasi, CEO of IPASA, “Through this initiative, working collaboratively with stakeholders at every level of the healthcare supply chain, we can bring real and meaningful change to those affected, including family members and care givers, through smart and efficient strategies.” The globally agreed definition of a rare disease is any medical condition with a specific pattern of clinical signs, symptoms, and findings that affects fewer than or equal to 1 in 2000 persons in a population. “Most are genetic, and some are inherited and passed down in families,” Malherbe says. “Some affect only the patient’s genetic recipe, while others may be acquired during life due to infection, trauma, or environmental effects. For many, the cause is still unknown. “These conditions mainly affect children, as they are largely incurable and many are life-threatening. Some require specialised and co-ordinated care, some have limited and expensive treatment options, while others have no information or effective treatments at all,” she adds. The RDAI is calling for a patient-centred care model built on equitable access, transparency and efficiency. Naturally, this model calls for the open participation of patients, the healthcare industry, health professionals, and the Government. “The most critical elements are robust diagnosis standards, improved access to treatment, data collection and management, co-ordination of care, measurement of outcomes and ongoing collaborative research,” du Plessis says. “We need to establish rare disease advisory committees, map gaps and opportunities, establish system requirements, create a roadmap and plan a phased implementation with clear timelines.” The RDAI states that these policy development steps would be a start in quantifying the disease burden and defining standards of care. This would be followed by building and strengthening the capacity to facilitate appropriate diagnosis, treatment, continuity and data monitoring. Thoneshan Naidoo, Chief Executive Officer of the Health Funders Association noted that, “We appreciate the unique opportunity provided by RDAI which enables stakeholders across the industry to work together and identify strategies that improve equitable access to the appropriate diagnosis, treatment and healthcare services for rare disease patients, in an affordable and sustainable manner, taking account of the other pressing needs across the healthcare system.” “True innovation in healthcare is only possible through partnerships and joint advocacy efforts that raise awareness and improve access to treatment. Our long-term goal is the development of a rare diseases policy framework and guidelines for coordinated care,” says Pharasi. “Our members are united in the commitment to unlocking improved patient outcomes and improving access to services and robust health needs assessment facilities.” he concludes. About RDAI The Rare Diseases Access Initiative (RDAI) is dedicated to advocating for improved healthcare access, policy development, and patient support for those affected by rare diseases in South Africa. The initiative brings together key healthcare stakeholders, including pharmaceutical associations, funders, genetic specialists, and patient advocacy groups, to drive impactful change. About RDSA Founded in 2013, Rare Diseases South Africa (RDSA) is a non-profit organisation advocating to ensure that people living with rare diseases and congenital disorders experience greater recognition, support, improved health service and better overall quality of life. Started out of personal need following the diagnosis of organisation founder, Kelly du Plessis' son, it became evident that there was a lack of awareness and support for rare diseases in general in South Africa. About IPASA The Innovative Pharmaceutical Association South Africa (IPASA) is a voluntary trade association representing 24 leading pharmaceutical companies committed to research, development, and innovation. Our mission is to drive healthcare advancement by advocating for policies that improve patient access to safe, high-quality, and affordable medicines.
Gastroenterologist Dr Barbara Makumbi explains the toll acid reflux can take on your health
February 26, 2025
Gastroenterologist Dr. Barbara Makumbi discusses common risk factors and offers tips for managing reflux and the longer-term condition known as gastroesophageal reflux disease (GORD).
More Posts